Donald Trump nominated Robert F. Kennedy Jr., a vaccine skeptic and harsh critic of federal health agencies, to be his ...

Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F. Kennedy Jr. to be the next secretary of the Department of Health and Human ...

Shares of vaccine-makers fell after reports that Donald Trump is expected to nominate vaccine skeptic Robert F. Kennedy Jr.

Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and ...

Shares of Moderna Inc. MRNA shed 6.86% to $46.83 Friday, on what proved to be an all-around favorable trading session for the ...

The stock price of Moderna (NASDAQ:MRNA) has seen a sharp 48% fall this year. From its lows of around $50, it is expected to see a rebound after posting a solid Q3 beat. The company reported ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

TD Cowen decreased their price objective on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. Leerink Partners ...

Moderna continues to focus on developing cancer treatment along ... "ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock ...

Currently, the analyst consensus on Moderna is a Moderate Buy with an average price target of $93.62, an 86.20% upside from current levels. In a report released today, Morgan Stanley also maintained a ...